Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, noviembre 04
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Pelthos Therapeutics Inc
PTHS
AMEX
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$10.78
-0.74
-6.42%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Fusiones y adquisiciones:
Castle Creek Bioscience announced it will be merged with Pelthos Therapeutics (PTHS) on Friday, October 30, 2026
Pelthos Therapeutics Financials
Pelthos Therapeutics (PTHS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the analyst consensus estimate of $(3.05) by 117.05 percent. This is a 23.05 percent decrease over losses of $(5.38) per share
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
PRO
Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(3.09) per share which beat the analyst consensus estimate of $(3.81) by 18.9 percent. The company reported quarterly sales of $10.906 million which beat
Benzinga Newsdesk
Earnings Scheduled For March 19, 2026
Benzinga Insights
PRO
Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the analyst consensus estimate of $(4.13) by 66.34 percent. This is a 115.36 percent decrease over losses of $(3.19) per share
Benzinga Newsdesk
PRO
Pelthos Therapeutics Q3 EPS $(5.30) Misses $(0.55) Estimate, Sales $7.406M Beat $4.380M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of $(0.55) by 863.64 percent. The company reported quarterly sales of $7.406 million which beat
Benzinga Newsdesk
